Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and four have assigned a strong buy rating to the company.
Several research analysts have commented on GLX shares. Citigroup raised Bradmer Pharmaceuticals to a “hold” rating in a research report on Tuesday, February 24th. Chardan Capital raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, May 4th.
Get Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
